Molecule News and Research

RSS

Single drop of blood in the brain can activate autoimmune response akin to multiple sclerosis

A new study from the Gladstone Institutes shows that a single drop of blood in the brain is sufficient to activate an autoimmune response akin to multiple sclerosis (MS). This is the first demonstration that introduction of blood in the healthy brain is sufficient to cause peripheral immune cells to enter the brain, which then go on to cause brain damage.

12 Oct 2015

UConn researchers sequence RNA of most complicated gene

UConn researchers have sequenced the RNA of the most complicated gene known in nature, using a hand-held sequencer no bigger than a cell phone.

From Oxford Nanopore Technologies 12 Oct 2015

Proposed thin-plate model sheds light on structural basis of chromosomal aberrations in cancer cells

During cell division, each metaphase chromosome contains a single enormously long DNA molecule that is associated with histone proteins and forms a long chromatin filament with many nucleosomes.

9 Oct 2015

Scientists map EGFRvIII mutant that causes brain cancer

A team of Ludwig Cancer Research scientists has mapped out how a mutant version of the epidermal growth factor receptor (EGFR) known as EGFRvIII specifically drives critical processes that alter the reading of the genome to fuel the growth of the brain cancer glioblastoma multiforme (GBM) and--most important--how each process is linked to the other.

9 Oct 2015

New partnership to deliver world-class healthcare through collaborative scientific research

A new partnership which harnesses world-class expertise will ensure patients benefit sooner from new treatments, diagnostics and prevention strategies.

9 Oct 2015

Researchers reveal new subtypes of invasive lobular carcinoma

Researchers from the UNC Lineberger Comprehensive Cancer Center and other academic centers have revealed new subtypes of invasive lobular carcinoma, the second most commonly diagnosed invasive breast cancer type. The findings could lead to personalized treatment approaches for the disease.

9 Oct 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

8 Oct 2015

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced that it has extended its strategic collaboration with Merck & Co., Inc., Kenilworth NJ., (known as MSD outside the United States and Canada) for the discovery and development of drug candidates for the treatment of chronic and neuropathic pain.

8 Oct 2015

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

Disabling a cancer-causing pathway and administering an immune-molecule-based mop-up therapy eradicated a specific type of breast tumor in mice, according to researchers in the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

New data analysis platform reveals major flaw in GC-MS process

A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.

7 Oct 2015

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

Rhythmic expression of key genes is essential for maintaining proper timekeeping of the body's clock. In addition, rhythmic degradation of clockwork proteins is also crucial. However, surprisingly, researchers know little about these specific processes.

7 Oct 2015

Binghamton University biochemist finds new way to fight cancer

A Binghamton University biochemist has discovered a new way to fight cancer, one that attacks only the cancer cells and promises fewer side effects. He hunts hedgehogs.

7 Oct 2015

NIH researchers discover why certain immune responses can be harmful to the brain

National Institutes of Health scientists studying inflammation of the brain have discovered why certain immune responses, which typically help cells recognize and fight viral and bacterial infections, can sometimes be harmful to the brain. Many brain disorders involve the death of neurons, or nerve cells, but how these neurons die is not well understood.

7 Oct 2015

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

PTC Therapeutics, Inc., today announced that clinical data from the company's joint development program with Roche and the SMA Foundation in spinal muscular atrophy (SMA) were presented at the 20th International Congress of the World Muscle Society (WMS) in Brighton, U.K.

5 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Unique combination opens up novel applications in nano-engineering

Scientists from Ludwig-Maximilians-Universitaet in Munich have developed a new class of molecular motors that rotate unidirectionally at speeds of up to 1 kHz when exposed to sunlight at room temperature.

30 Sep 2015

Saint Louis University receives NIH grant to investigate development of new drugs to treat bone diseases

David Griggs, Ph.D., director of biology at Saint Louis University's Center for World Health & Medicine, has received a $1 million R01 grant from the National Institutes of Health to investigate the development of what could be a new class of drugs to treat bone diseases.

30 Sep 2015

Study raises hope for reducing life-threatening respiratory problems in infants

St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).

30 Sep 2015

Researchers unlock structural details of key protein to treat neuromuscular disease

Researchers at Rice University and Baylor College of Medicine have unlocked the structural details of a protein seen as key to treating a neuromuscular disease.

30 Sep 2015

Molecule News and Research

Single drop of blood in the brain can activate autoimmune response akin to multiple sclerosis

UConn researchers sequence RNA of most complicated gene

Proposed thin-plate model sheds light on structural basis of chromosomal aberrations in cancer cells

Scientists map EGFRvIII mutant that causes brain cancer

New partnership to deliver world-class healthcare through collaborative scientific research

Researchers reveal new subtypes of invasive lobular carcinoma

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Bionomics, Merck extend collaboration to develop drug candidates for treatment of chronic and neuropathic pain

Immune-molecule-based mop-up therapy reduces specific type of breast tumor in mice

New data analysis platform reveals major flaw in GC-MS process

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

Binghamton University biochemist finds new way to fight cancer

NIH researchers discover why certain immune responses can be harmful to the brain

Clinical data from spinal muscular atrophy program presented at 20th International WMS Congress

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Unique combination opens up novel applications in nano-engineering

Saint Louis University receives NIH grant to investigate development of new drugs to treat bone diseases

Study raises hope for reducing life-threatening respiratory problems in infants

Researchers unlock structural details of key protein to treat neuromuscular disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News